Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553782 · ClinicalTrials.gov registry record · Early Phase 1
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
A Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05553782: Recruiting Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, sponsored by Brigham and Women's Hospital.
NCT05553782 is a Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05553782, a Early Phase 1 study of Head and Neck Cancer and Squamous Cell Carcinoma of Head and Neck, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice
Primary Outcome
All grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Implantable Microdevice (IMD)
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-11-01 |
| Est. Completion | 2029-08-01 |
| Phase | Early Phase 1 |
What NCT05553782 shows while recruiting
NCT05553782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower).
The record links to 4 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Implantable Microdevice (IMD) is the first listed.
NCT05553782 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05553782 about?
NCT05553782 is a clinical study titled "Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers". This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: \-- implantable microdevice
What is the current status of trial NCT05553782?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-11-01. Estimated completion is 2029-08-01.
What conditions does trial NCT05553782 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland.
What interventions are being tested in trial NCT05553782?
The interventions under investigation include: Implantable Microdevice (IMD) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05553782?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05553782 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05553782's enrollment target sits among peer trials
30 174th of 250 higher than 66 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intraoral Hypothermia Device for Preserving Taste During Radiation
RECRUITING · Early Phase 1
-
Smoking Cessation Treatment for Head & Neck Cancer Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma
COMPLETED · Early Phase 1
-
Intratumoral Microdosing of TAK-981 in Head and Neck Cancer
COMPLETED · Early Phase 1
-
Curcumin Biomarker Trial in Head and Neck Cancer
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI